TWI799923B - 硫代咪唑烷酮藥物在治療covid-19疾病中的用途 - Google Patents

硫代咪唑烷酮藥物在治療covid-19疾病中的用途 Download PDF

Info

Publication number
TWI799923B
TWI799923B TW110127077A TW110127077A TWI799923B TW I799923 B TWI799923 B TW I799923B TW 110127077 A TW110127077 A TW 110127077A TW 110127077 A TW110127077 A TW 110127077A TW I799923 B TWI799923 B TW I799923B
Authority
TW
Taiwan
Prior art keywords
thioimidazolidinone
covid
drugs
disease
treatment
Prior art date
Application number
TW110127077A
Other languages
English (en)
Other versions
TW202227065A (zh
Inventor
友之 童
馬連東
周千翔
嚴紅花
任志華
楊劍飛
Original Assignee
大陸商蘇州開拓藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商蘇州開拓藥業股份有限公司 filed Critical 大陸商蘇州開拓藥業股份有限公司
Publication of TW202227065A publication Critical patent/TW202227065A/zh
Application granted granted Critical
Publication of TWI799923B publication Critical patent/TWI799923B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110127077A 2020-12-31 2021-07-21 硫代咪唑烷酮藥物在治療covid-19疾病中的用途 TWI799923B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202011640468.9 2020-12-31
CN202011640468 2020-12-31
CN202110657053.0A CN113143924B (zh) 2020-12-31 2021-06-11 硫代咪唑烷酮药物在治疗covid-19疾病中的用途
CN202110657053.0 2021-06-11

Publications (2)

Publication Number Publication Date
TW202227065A TW202227065A (zh) 2022-07-16
TWI799923B true TWI799923B (zh) 2023-04-21

Family

ID=76875845

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110127077A TWI799923B (zh) 2020-12-31 2021-07-21 硫代咪唑烷酮藥物在治療covid-19疾病中的用途

Country Status (2)

Country Link
CN (1) CN113143924B (zh)
TW (1) TWI799923B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022141328A1 (zh) * 2020-12-31 2022-07-07 苏州开拓药业股份有限公司 硫代咪唑烷酮药物在治疗covid-19疾病中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
CN106810542A (zh) * 2015-11-30 2017-06-09 苏州开拓药业有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
CN106810542A (zh) * 2015-11-30 2017-06-09 苏州开拓药业有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 , FA CADEGIANI, et al., "Proxalutamide (GT0918) reduces the rate of hospitalization and death in COVID-19 male patients: a randomized double-blinded placebo-controlled trial", Research Square, Preprint v1, Europe PMC. 29 Dec 2020, https://europepmc.org/article/PPR/PPR258803.
期刊 , S WU, et al., "Suppression of androgen receptor (AR)-ACE2/TMPRSS2 axis by AR antagonists may be therapeutically beneficial for male COVID-2019 patients", SSRN, SSRN, Posted: 18 Jun 2020, http://dx.doi.org/10.2139/ssrn.3580526.;期刊 , FA CADEGIANI, et al., "Proxalutamide (GT0918) reduces the rate of hospitalization and death in COVID-19 male patients: a randomized double-blinded placebo-controlled trial", Research Square, Preprint v1, Europe PMC. 29 Dec 2020, https://europepmc.org/article/PPR/PPR258803. *

Also Published As

Publication number Publication date
TW202227065A (zh) 2022-07-16
CN113143924B (zh) 2023-04-14
CN113143924A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
EP3684353A4 (en) TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
EP3440081A4 (en) PYRROLO [1,2-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
IL289167A (en) The history of 2h-indazole and their use in the treatment of diseases
EP3607952A4 (en) USE OF CARRIMYCIN AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND / OR PREVENTION OF TUMORS
EP3440083A4 (en) IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
EP3969125A4 (en) USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES
EP3915985A4 (en) PYRROLOPYRIDINE DERIVATIVE AND ITS USE IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASE
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
TWI799923B (zh) 硫代咪唑烷酮藥物在治療covid-19疾病中的用途
EP3814326A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
EP3790866A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
EP3549596A4 (en) USE OF MICROCYSTINES FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE PREVENTION OR TREATMENT OF ORGANIC AND TISSUE FIBROSE DISEASES
EP4003355A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
PT3937948T (pt) Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares
EP3881843A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICAL COMPOSITION FOR IL-31 MEDIATED DISEASE
EP3766503A4 (en) USE OF A MICRORNA 210 INHIBITOR IN THE MANUFACTURING MEDICINAL PRODUCTS FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
EP3753579A4 (en) ANTI-TRAILR2 ANTIBODY TOXIN CONJUGATE AND ITS PHARMACEUTICAL USES IN ANTITUM ORTHERAPY
EP3644753A4 (en) METHODS FOR MAINTAINING AND IMPROVING RENAL FUNCTION IN PATIENTS WITH RENAL DISEASE AND STANDARD TREATMENT THERAPY
ITMI20021866A1 (it) Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.
EP3458058A4 (en) PHARMACEUTICAL COMPOSITION AND ITS USE IN THE TREATMENT OF AUTOIMMUNE DISEASES
EP4003997A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
EP4069251A4 (en) CETHROMYCIN SALTS AND POLYMORPHS FOR THE TREATMENT OF CETHROMYCIN SALTS AND POLYMORPHS